source
- Taysha and Neurogene close in on first Rett syndrome gene therapy as 2027 readouts loomTwo companies, Taysha Gene Therapies and Neurogene, are nearing the final stage of development for gene therapies targeting Rett syndrome, a rare neurodevelopmental disorder with limited treatment…
- U.S. biotechs capture 68% of global VC funding since 2025, led by Bay Area and BostonSince the start of 2025, U.S. biopharma firms have secured $37.2 billion in venture capital, representing about 68 % of the $54.5 billion raised worldwide. The San Francisco Bay Area and Boston do…